Madrigal Pharmaceuticals, Inc. $MDGL Stock Bought by Calamos Advisors LLC

Calamos Advisors LLC grew its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 83.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,009 shares of the biopharmaceutical company’s stock after purchasing an additional 1,367 shares during the period. Calamos Advisors LLC’s holdings in Madrigal Pharmaceuticals were worth $1,516,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Persistent Asset Partners Ltd acquired a new position in shares of Madrigal Pharmaceuticals in the 2nd quarter valued at about $29,000. Global Retirement Partners LLC acquired a new stake in Madrigal Pharmaceuticals during the second quarter worth about $34,000. Provenance Wealth Advisors LLC acquired a new stake in Madrigal Pharmaceuticals during the third quarter worth about $69,000. Root Financial Partners LLC acquired a new stake in Madrigal Pharmaceuticals during the third quarter worth about $82,000. Finally, GAMMA Investing LLC lifted its holdings in Madrigal Pharmaceuticals by 35.4% in the second quarter. GAMMA Investing LLC now owns 172 shares of the biopharmaceutical company’s stock worth $92,000 after acquiring an additional 45 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors.

Madrigal Pharmaceuticals Trading Up 8.3%

Shares of MDGL opened at $432.79 on Tuesday. Madrigal Pharmaceuticals, Inc. has a 1 year low of $353.54 and a 1 year high of $615.00. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.05 and a quick ratio of 2.94. The firm has a fifty day moving average of $484.73 and a 200-day moving average of $497.09.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 EPS for the quarter, topping the consensus estimate of ($1.09) by $2.92. Madrigal Pharmaceuticals had a negative net margin of 10.89% and a negative return on equity of 27.08%. The business had revenue of $431.27 million during the quarter, compared to analyst estimates of $404.17 million. During the same quarter in the prior year, the firm earned ($5.08) earnings per share. Equities analysts forecast that Madrigal Pharmaceuticals, Inc. will post -2.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on MDGL shares. Canaccord Genuity Group raised their target price on shares of Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Truist Financial reaffirmed a “buy” rating and set a $743.00 target price (up from $709.00) on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 4th. Wells Fargo & Company initiated coverage on Madrigal Pharmaceuticals in a research report on Monday, July 27th. They set an “overweight” rating and a $685.00 price target on the stock. Citigroup increased their price target on Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the stock a “buy” rating in a research report on Tuesday, November 3rd. Finally, The Goldman Sachs Group initiated coverage on Madrigal Pharmaceuticals in a report on Thursday, September 24th. They issued a “buy” rating and a $704.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $706.87.

Insider Activity at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, General Counsel Shannon T. Kelley sold 1,077 shares of the company’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $400.00, for a total value of $430,800.00. Following the completion of the transaction, the general counsel owned 10,397 shares in the company, valued at approximately $4,158,800. This represents a 9.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO William Sibold sold 5,221 shares of the company’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $542.39, for a total transaction of $2,831,818.19. Following the completion of the transaction, the chief executive officer owned 197,746 shares of the company’s stock, valued at approximately $107,255,452.94. This trade represents a 2.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 13,324 shares of company stock worth $7,011,982 in the last ninety days. 17.60% of the stock is owned by insiders.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania.

Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.

Madrigal’s work centers on advancing medicines for liver disease, with Rezdiffra serving as its first approved therapy.